

# EXHIBIT E



US009364435B2

(12) **United States Patent**  
**Yaworski et al.**

(10) **Patent No.:** **US 9,364,435 B2**  
(45) **Date of Patent:** **\*Jun. 14, 2016**

(54) **LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY**

(71) Applicant: **Protiva Biotherapeutics, Inc.**, Burnaby (CA)

(72) Inventors: **Edward Yaworski**, Maple Ridge (CA); **Kieu Lam**, Surrey (CA); **Lloyd Jeffs**, Delta (CA); **Lorne Palmer**, Vancouver (CA); **Ian MacLachlan**, Mission (CA)

(73) Assignee: **PROTIVA BIOTHERAPEUTICS, INC.**, Burnaby, BC (CA)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/462,441**

(22) Filed: **Aug. 18, 2014**

(65) **Prior Publication Data**

US 2015/0164799 A1 Jun. 18, 2015

**Related U.S. Application Data**

(63) Continuation of application No. 13/928,309, filed on Jun. 26, 2013, now Pat. No. 8,822,668, which is a continuation of application No. 13/253,917, filed on Oct. 5, 2011, now Pat. No. 8,492,359, which is a continuation of application No. 12/424,367, filed on Apr. 15, 2009, now Pat. No. 8,058,069.

(60) Provisional application No. 61/045,228, filed on Apr. 15, 2008.

(51) **Int. Cl.**

**C12N 15/11** (2006.01)  
**A61K 9/127** (2006.01)  
**A61K 48/00** (2006.01)  
**C07H 21/00** (2006.01)  
**C07J 9/00** (2006.01)  
**C12N 15/113** (2010.01)

(52) **U.S. Cl.**

CPC ..... **A61K 9/1272** (2013.01); **A61K 9/1271** (2013.01); **A61K 48/0025** (2013.01); **C07H 21/00** (2013.01); **C07J 9/00** (2013.01); **C12N 15/111** (2013.01); **C12N 15/113** (2013.01); **C12N 2310/14** (2013.01); **C12N 2320/32** (2013.01)

(58) **Field of Classification Search**

CPC . C12N 15/113; C12N 2310/14; A61K 9/1271  
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,394,448 A 7/1983 Szoka, Jr. et al.  
4,438,052 A 3/1984 Weder et al.

4,897,355 A 1/1990 Eppstein et al.  
5,013,556 A 5/1991 Woodle et al.  
5,171,678 A 12/1992 Behr et al.  
5,208,036 A 5/1993 Eppstein et al.  
5,225,212 A 7/1993 Martin et al.  
5,264,618 A 11/1993 Felgner et al.  
5,279,833 A 1/1994 Rose  
5,283,185 A 2/1994 Epand et al.  
5,320,906 A 6/1994 Eley et al.  
5,334,761 A 8/1994 Gebeyehu et al.  
5,545,412 A 8/1996 Eppstein et al.  
5,578,475 A 11/1996 Jessee  
5,627,159 A 5/1997 Shih et al.  
5,641,662 A 6/1997 Debs et al.  
5,656,743 A 8/1997 Busch et al.  
5,674,908 A 10/1997 Haces et al.  
5,703,055 A 12/1997 Felgner et al.  
5,705,385 A 1/1998 Bally et al.  
5,736,392 A 4/1998 Hawley-Nelson et al.  
5,820,873 A 10/1998 Choi et al.  
5,877,220 A 3/1999 Schwartz et al.  
5,885,613 A 3/1999 Holland et al.  
5,958,901 A 9/1999 Dwyer et al.  
5,976,567 A 11/1999 Wheeler et al.  
5,981,501 A 11/1999 Wheeler et al.  
6,020,202 A 2/2000 Jessee

(Continued)

FOREIGN PATENT DOCUMENTS

CA 2309727 A1 4/1999  
CA 2271582 A1 11/1999

(Continued)

OTHER PUBLICATIONS

Arpicco, S., et al., "Preparation and Characterization of Novel Cationic Lipids Developed for Gene Transfection," Proceed. Int'l Symp. Control. Rel. Bioact. Mater. (Controlled Release Society, Inc.), 1999, vol. 26, pp. 759-760.  
Arpicco, S., et al., "Synthesis, characterization and transfection activity of new saturated and unsaturated cationic lipids," IL Farmaco, 2004, vol. 59, pp. 869-878.  
Ballas, N., et al., "Liposomes bearing a quaternary ammonium detergent as an efficient vehicle for functional transfer of TMV-RNA into plant protoplasts," Biochimica et Biophysica Acta, 1988, vol. 939, pp. 8-18.  
Barinaga, M., "Step Taken Toward Improved Vectors for Gene Transfer," Science, 1994, vol. 266, p. 1326.  
Bass, "The Short Answer," Nature, 2001, 411: 428-9.  
Beale, G., et al., "Gene Silencing Nucleic Acids Designed by Scanning Arrays: Anti-EGFR Activity of siRNA, Ribozyme and DNA Enzymes Targeting a Single Hybridization-accessible Region using the Same Delivery System," Journal of Drug Targeting, 2003, vol. 11, No. 7, pp. 449-456.

(Continued)

Primary Examiner — Brian Whiteman

(74) Attorney, Agent, or Firm — Kilpatrick Townsend & Stockton LLP

(57) **ABSTRACT**

The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.

(56)

References Cited

FOREIGN PATENT DOCUMENTS

U.S. PATENT DOCUMENTS

6,020,526 A 2/2000 Schwartz et al.  
 6,034,135 A 3/2000 Schwartz et al.  
 6,051,429 A 4/2000 Hawley-Nelson et al.  
 6,075,012 A 6/2000 Gebeyehu et al.  
 6,165,501 A 12/2000 Tirosh et al.  
 6,172,049 B1 1/2001 Dwyer et al.  
 6,251,939 B1 6/2001 Schwartz et al.  
 6,284,267 B1 9/2001 Aneja  
 6,287,591 B1 9/2001 Semple et al.  
 6,339,173 B1 1/2002 Schwartz et al.  
 6,376,248 B1 4/2002 Hawley-Nelson et al.  
 6,534,484 B1 3/2003 Wheeler et al.  
 6,586,410 B1 7/2003 Wheeler et al.  
 6,638,529 B2 10/2003 Schwartz et al.  
 6,649,780 B1 11/2003 Eibl et al.  
 6,671,393 B2 12/2003 Hays et al.  
 6,696,424 B1 2/2004 Wheeler et al.  
 6,815,432 B2 11/2004 Wheeler et al.  
 6,858,224 B2 2/2005 Wheeler et al.  
 7,166,745 B1 1/2007 Chu et al.  
 7,422,902 B1 9/2008 Wheeler et al.  
 7,479,573 B2 1/2009 Chu et al.  
 7,601,872 B2 10/2009 Chu et al.  
 7,687,070 B2 3/2010 Gebeyehu et al.  
 7,745,651 B2 6/2010 Heyes et al.  
 7,799,565 B2 9/2010 MacLachlan et al.  
 7,803,397 B2 9/2010 Heyes et al.  
 7,807,815 B2 10/2010 MacLachlan et al.  
 7,838,658 B2 11/2010 MacLachlan et al.  
 7,901,708 B2 3/2011 MacLachlan et al.  
 7,915,450 B2 3/2011 Chu et al.  
 7,982,027 B2 7/2011 MacLachlan et al.  
 8,058,068 B2 11/2011 Hawley-Nelson et al.  
 8,058,069 B2 11/2011 Yaworski et al.  
 8,101,741 B2 1/2012 MacLachlan et al.  
 8,158,827 B2 4/2012 Chu et al.  
 8,188,263 B2 5/2012 MacLachlan et al.  
 8,227,443 B2 7/2012 MacLachlan et al.  
 8,236,943 B2\* 8/2012 Lee et al. .... 536/24.5  
 8,283,333 B2 10/2012 Yaworski et al.  
 8,455,455 B1 6/2013 Robbins et al.  
 8,492,359 B2\* 7/2013 Yaworski et al. .... 514/44 A  
 8,513,403 B2 8/2013 MacLachlan et al.  
 8,569,256 B2 10/2013 Heyes et al.  
 8,598,333 B2 12/2013 MacLachlan et al.  
 8,822,668 B2\* 9/2014 Yaworski et al. .... 536/24.5  
 9,006,417 B2\* 4/2015 Yaworski et al. .... 536/24.5  
 2001/0048940 A1 12/2001 Tousignant et al.  
 2003/0069173 A1 4/2003 Hawley-Nelson et al.  
 2003/0072794 A1 4/2003 Boulikas  
 2003/0077829 A1 4/2003 MacLachlan  
 2003/0143732 A1 7/2003 Fosnaugh et al.  
 2004/0063654 A1 4/2004 Davis et al.  
 2004/0142892 A1 7/2004 Finn et al.  
 2004/0253723 A1 12/2004 Tachas et al.  
 2004/0259247 A1 12/2004 Tusch et al.  
 2005/0064595 A1 3/2005 MacLachlan et al.  
 2005/0118253 A1 6/2005 MacLachlan et al.  
 2005/0260757 A1 11/2005 Gebeyehu et al.  
 2006/0008910 A1 1/2006 MacLachlan et al.  
 2006/0147514 A1 7/2006 Gebeyehu et al.  
 2006/0228406 A1 10/2006 Chiou et al.  
 2006/0240093 A1 10/2006 MacLachlan et al.  
 2007/0042031 A1 2/2007 MacLachlan et al.  
 2007/0202598 A1 8/2007 Chu et al.  
 2007/0202600 A1 8/2007 Chu et al.  
 2009/0143583 A1 6/2009 Chu et al.  
 2009/0291131 A1 11/2009 MacLachlan et al.  
 2010/0130588 A1 5/2010 Yaworski et al.  
 2010/0159593 A1 6/2010 Chu et al.  
 2012/0058188 A1 3/2012 MacLachlan et al.  
 2012/0136073 A1 5/2012 Yang et al.  
 2012/0183581 A1 7/2012 Yaworski et al.

CA 2330741 A1 11/1999  
 CA 2397016 A1 7/2001  
 CA 2513623 8/2004  
 JP 03-126211 5/1991  
 JP 05-202085 8/1993  
 JP 06-080560 3/1994  
 JP 2002-525063 8/2002  
 JP 2003-505401 2/2003  
 JP 2007-524349 8/2007  
 WO 91/16024 A1 10/1991  
 WO 93/05162 A1 3/1993  
 WO 93/12240 A1 6/1993  
 WO 93/12756 A2 7/1993  
 WO 93/24640 A2 12/1993  
 WO 93/25673 A1 12/1993  
 WO 95/02698 A1 1/1995  
 WO 95/18863 A1 7/1995  
 WO 95/35301 A1 12/1995  
 WO 96/02655 A1 2/1996  
 WO 96/10390 A1 4/1996  
 WO 96/40964 A2 12/1996  
 WO 96/41873 A1 12/1996  
 WO 98/51285 A2 11/1998  
 WO 00/03683 A2 1/2000  
 WO 00/15820 A1 3/2000  
 WO 00/62813 A2 10/2000  
 WO 01/05374 A1 1/2001  
 WO 01/05873 A1 1/2001  
 WO 01/75164 A2 10/2001  
 WO 01/93836 12/2001  
 WO 02/34236 A2 5/2002  
 WO 02/087541 A1 11/2002  
 WO 03/097805 A2 11/2003  
 WO 2004/065546 A2 8/2004  
 WO 2004/110499 A1 12/2004  
 WO 2005/007196 A2 1/2005  
 WO 2005/026372 A1 3/2005  
 WO 2005/035764 A1 4/2005  
 WO 2005/120152 A2 12/2005  
 WO 2006/002538 A1 1/2006  
 WO 2006/053430 A1 5/2006  
 WO 2007/056861 A1 5/2007  
 WO 2009/086558 A1 7/2009  
 WO 2009/111658 A2 9/2009  
 WO 2010/042877 A1 4/2010  
 WO 2010/048228 A2 4/2010  
 WO 2010/088537 A2 8/2010  
 WO 2010/105209 A1 9/2010

OTHER PUBLICATIONS

Behr, J.-P., "Synthetic Gene-Transfer Vectors," *Acc. Chem. Res.*, 1993, vol. 26, pp. 274-278.  
 Brigham, K., et al., "Rapid Communication: In vivo Transfection of Murine Lungs with a Functioning Prokaryotic Gene Using a Liposome Vehicle," *The American Journal of the Medical Sciences*, vol. 298, No. 4, pp. 278-281.  
 Brummelkamp, et al., "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells," *Science*, 2002, V. 296, pp. 550-553.  
 Cevc, G., "How Membrane Chain-Melting Phase-Transition Temperature is Affected by the Lipid Chain Asymmetry and Degree of Unsaturation: An Effective Chain-Length Model," *Biochemistry*, 1991, vol. 30, pp. 7186-7193.  
 Chonn et al., "Recent advances in liposomal drug-delivery systems," *Current Opinion in Biotechnology*, 1995, vol. 6, pp. 698-708.  
 Cortesi, R., et al., "Effect of cationic liposome composition on in vitro cytotoxicity and protective effect on carried DNA," *International Journal of Pharmaceutics*, 1996, vol. 139, pp. 69-78.  
 Crystal, R., "Transfer of Genes to Humans: Early Lessons and Obstacles to Success," *Science*, 1995, vol. 270, pp. 404-410.  
 Culver K., "The First Human Gene Therapy Experiment," *Gene Therapy: A Handbook for Physicians*, 1994, pp. 33-40.

(56)

## References Cited

## OTHER PUBLICATIONS

- Dwarki, V.J., et al., "Cationic Liposome-Mediated RNA Transfection," *Methods in Enzymology*, 1993, vol. 217, pp. 644-654.
- Elbashir, et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," *Nature*, May 2001, pp. 494-498, vol. 411.
- Enoch, H., et al., "Formation and properties of 1000-Å-diameter, single-bilayer phospholipid vesicles," *Proc. Natl. Acad. Sci. USA*, 1979, vol. 76, No. 1, pp. 145-149.
- Felgner, J., et al., "Cationic Lipid-Mediated Transfection in Mammalian Cells: 'Lipofection,'" *J. Tiss. Cult. Meth.*, 1993, vol. 15, pp. 63-68.
- Felgner, J., et al., "Enhanced Gene Delivery and Mechanism Studies with a Novel Series of Cationic Lipid Formulations," *The Journal of Biological Chemistry*, 1994, vol. 269, No. 4, pp. 2550-2561.
- Felgner, P., et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure," *Proc. Natl. Acad. Sci. USA*, 1987, vol. 84, pp. 7413-7417.
- Felgner, P.L., et al., "Cationic Liposome Mediated Transfection," *Proc. West. Pharmacol. Soc.*, 1989, vol. 32, pp. 115-121.
- Gao, X., et al., "A Novel Cationic Liposome Reagent for Efficient Transfection of Mammalian Cells," *Biochem. Biophys. Res. Comm.*, 1991, vol. 179, No. 1, pp. 280-285.
- Gershon, H., et al., "Mode of Formation and Structural Feature of DNA-Cationic Liposome Complexes Used for Transfection," *Biochemistry*, 1993, vol. 32, pp. 7143-7151.
- Global Newswire, retrieved from <http://globalnewswire.com> on Feb. 27, 2013, Tekmira sues Alnylam Pharmaceuticals for repeated misuse of tradesecrets and confidential information, Mar. 16, 2011, pp. 1-3.
- Guy-Caffey, J., et al., "Novel Polyaminolipids Enhance the Cellular Uptake of Oligonucleotides," *The Journal of Biological Chemistry*, 1995, vol. 270, No. 52, pp. 31391-31396.
- Hawley-Nelson, P., et al., "LipofectAmine™ Reagent: A New, Higher Efficiency Polycationic Liposome Transfection Reagent," *Focus*, 1993, vol. 15, No. 3, pp. 73-80.
- Heyes et al., "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids," *Journal of Controlled Release*, 2005, vol. 107, pp. 276-287.
- Heyes et al., "Synthesis of novel cationic lipids: effect of structural modification on the efficiency of gene transfer," *J. Med. Chem.*, 2002, vol. 45, pp. 99-114.
- Hyde, S., et al., "Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy," *Nature*, 1993, vol. 362, pp. 250-255.
- Jiang, L., et al., "Comparison of protein precipitation methods for sample preparation prior to proteomic analysis," *Journal of Chromatography A*, 2004, vol. 1023, pp. 317-320.
- Juliano, R., et al., "The Effect of Particle Size and Charge on the Clearance Rates of Liposomes and Liposome Encapsulated Drugs," *Biochem. Biophys. Res. Commun.*, 1975, vol. 63, No. 3, pp. 651-658.
- Keough, K., "Influence of chain unsaturation and chain position on thermotropism and intermolecular interactions in membranes," *Biochem. Soc. Transactions*, 1990, vol. 18, No. 5, pp. 835-837.
- Krichevsky, A. et al., "RNAi functions in cultured mammalian neurons," *PNAS*, 99(18):11926-29, 2002.
- Lawrence et al. "The formation, characterization and stability of non-ionic surfactant vesicles," *S.T.P. Pharma Sciences*, 1996, vol. 6, No. 1, pp. 49-60.
- Lawrence et al., "Synthesis and aggregation properties of dialkyl polyoxyethylene glycerol ethers," *Chemistry and Physics of Lipids*, 1996, 82(2):89-100.
- Legendre, J.-Y. et al., "Delivery of Plasmid DNA into Mammalian Cell Lines Using pH-Sensitive Liposomes: Comparison with Cationic Liposomes," *Pharm. Res.*, 1992, vol. 9, No. 10, pp. 1235-1242.
- Leventis, R., et al., "Interactions of mammalian cells with lipid dispersions containing novel metabolizable cationic amphiphiles," *Biochem. Biophys. Acta*, 1990, vol. 1023, pp. 124-132.
- Liu, et al., "Cationic Liposome-mediated Intravenous Gene Delivery," *J. Biol. Chem.*, 1995, V. 270, pp. 24864-24870.
- Marshall, E., "Gene Therapy's Growing Pains," *Science*, 1995, vol. 269, pp. 1050-1055.
- Murahashi et al., "Synthesis and evaluation of neoglycolipid for liposome modification," *Biol. Pharm. Bull.*, 1997, 20(6):704-707.
- Orkin, S., et al., NIH Report, Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995.
- Parr et al., Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles, *Biochimica et Biophysica Acta*, 1994, 1195:21-30.
- Paul, C., et al., "Effective expression of small interfering RNA in human cells," *Nature Biotech.*, 2002, vol. 20, pp. 505-508.
- Puyal, C., et al., "A new cationic liposome encapsulating genetic material: A potential delivery system for polynucleotides," *Eur. J. Biochem.*, 1995, vol. 228, pp. 697-703.
- Sawada et al., "Microemulsions in supercritical CO<sub>2</sub> utilizing the polyethyleneglycol dialkylglycerol and their use for the solubilization of hydrophiles," *Dyes and Pigments*, 2005, pp. 64-74, vol. 65.
- Shin, et al., "Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids," *Journal of Controlled Release*, 2003, vol. 91, pp. 187-200.
- Song et al., "Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes," *Biochimica et Biophysica Acta*, 2002, 1558:1-13.
- Sorensen, et al., "Gene Silencing by Systemic Delivery of Synthetic siRNAs in Adult Mice", *J. Biol. Chem.*, 2003, V. 327, pp. 761-766.
- Spagnou, S., et al., "Lipidic Carriers of siRNA: Differences in the Formulation, Cellular Uptake, and Delivery with Plasmid DNA," *Biochemistry*, 2004, vol. 43, pp. 13348-13356.
- Stamatatos, L., et al., "Interactions of Cationic Lipid Vesicles with Negatively Charged Phospholipid Vesicles and Biological Membranes," *Biochemistry*, 1988, vol. 27, pp. 3917-3925.
- Szoka, F., et al., "Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes)," *Ann. Rev. Biophys. Bioeng.*, 1980, vol. 9, pp. 467-508.
- Szoka, F., et al., "Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation," *Proc. Natl. Acad. Sci. USA*, 1978, vol. 75, No. 9, pp. 4194-4198.
- Templeton, "Cationic Liposome-mediated Gene Delivery In vivo", *Bioscience Reports*, 2002, vol. 22, No. 2, pp. 283-295.
- Van Der Woude, I., et al., "Parameters influencing the introduction of plasmid DNA into cells by the use of synthetic amphiphiles as a carrier system," *Biochimica et Biophysica Acta*, 1995, vol. 1240, pp. 34-40.
- Wheeler, et al., "Stabilized Plasmid-lipid Particles: Constructions and Characterization," *Gene Therapy*, V. 6, pp. 271-281.
- Wilson, R., et al., "Counterion-Induced Condensation of Deoxyribonucleic Acid, A Light-Scattering Study," *Biochemistry*, 1979, vol. 18, No. 11, pp. 2192-2196.
- Woodle, M.C., et al., "Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes," *Biochimica et Biophysica Acta*, 1992, vol. 1105, pp. 193-200.
- Zhu, N., et al., "Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice," *Science*, 1993, vol. 261, pp. 209-211.

\* cited by examiner




FIG. 1A

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.